세포 치료 기술 시장 : 제공 제품 및 서비스별, 치료법 유형별, 제조 공정별, 투여 방법별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Cell Therapy Technologies Market is projected to grow by USD 14.02 billion at a CAGR of 14.37% by 2032.

Cell Therapy Technologies Market Introduction

Cell therapy technologies are the enabling platforms behind autologous and allogeneic therapies, including CAR T-cell therapy, tumor-infiltrating lymphocytes, natural killer cell therapies, mesenchymal stromal cell applications, hematopoietic stem cell products, and induced pluripotent stem cell-derived programs. The technology stack spans cell isolation, activation, gene transfer or gene editing, expansion, closed-system bioprocessing, cryopreservation, release testing, chain-of-identity controls, and temperature-controlled logistics.

The sector has moved from scientific promise to regulated commercialization. The U.S. FDA approved the first CAR T-cell therapies in 2017, and regulators in the United States, Europe, Japan, China, and South Korea have since advanced multiple cell and gene therapy pathways. For industry leaders, the central market question is no longer whether cell therapy can deliver clinical value, but how manufacturing platforms, quality systems, and digital infrastructure can scale these therapies reliably, safely, and cost-effectively.

Transformative Shifts Reshaping Cell Therapy Technologies

The cell therapy technologies landscape is shifting from manual, open, and site-specific workflows toward closed, automated, and digitally traceable manufacturing. This transformation is being driven by the need to reduce contamination risk, shorten vein-to-vein time for autologous therapies, improve batch consistency, and support broader patient access. Modular cleanrooms, automated cell processing systems, single-use bioreactors, rapid sterility testing, and integrated quality analytics are becoming essential competitive differentiators.

Scientific innovation is also reshaping demand. Allogeneic cell therapy, iPSC-derived platforms, CRISPR-based engineering, non-viral delivery, and next-generation immune cell therapies are expanding the addressable treatment landscape beyond hematologic malignancies into solid tumors, autoimmune diseases, inflammatory disorders, and regenerative medicine. At the same time, regulators are raising expectations for comparability, potency assays, long-term follow-up, and post-market evidence, making process control and data integrity central to commercial success.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is creating cumulative value across the cell therapy technology lifecycle. In discovery and translational research, AI supports target selection, antigen escape analysis, construct optimization, biomarker discovery, and patient stratification. In manufacturing, machine learning can help predict culture performance, detect deviations earlier, optimize media and feeding strategies, and support image-based assessment of cell morphology, viability, and phenotype.

The strongest near-term impact is expected in quality control, release analytics, scheduling, and supply chain orchestration, where AI can reduce manual review burdens and improve decision speed. However, adoption must remain aligned with GxP expectations, validated datasets, cybersecurity controls, audit trails, and human oversight. Companies that treat AI as a governed quality and productivity layer rather than an isolated software tool will be better positioned to improve scalability without compromising patient safety.

Key Regional Insights for Cell Therapy Technologies

North America remains a leading region for cell therapy technologies due to its concentration of biotechnology companies, academic medical centers, contract development and manufacturing organizations, venture funding, and FDA programs such as Regenerative Medicine Advanced Therapy designation. The United States anchors clinical development and commercialization, while Canada contributes strong translational research, hospital networks, and cell manufacturing capabilities.

Europe benefits from the European Medicines Agency framework for advanced therapy medicinal products, strong public research systems, and established manufacturing hubs in Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is expanding rapidly as Japan applies regenerative medicine-specific regulatory pathways, China scales domestic cell therapy trials and manufacturing, South Korea invests in advanced biopharmaceutical infrastructure, and Australia and Singapore strengthen clinical and process development ecosystems.

Latin America is emerging through Brazil and Mexico, where regulatory modernization, oncology demand, and partnerships with global developers are increasing visibility, although reimbursement and cold-chain constraints remain material. The Middle East, led by Gulf investment in advanced healthcare infrastructure, is building specialist centers and regional biomanufacturing ambitions. Africa remains earlier in adoption, but South Africa, Egypt, and selected academic networks are developing capacity through clinical collaborations, workforce training, and improved biobanking and laboratory infrastructure.

Key Group Insights Across Strategic Economic Blocs

ASEAN is gaining relevance through Singapore's biomanufacturing base, Thailand's medical tourism ecosystem, Malaysia's biologics infrastructure, and expanding clinical research capabilities across the region. The GCC is prioritizing precision medicine, oncology care, and local biopharmaceutical capacity, with Saudi Arabia, the United Arab Emirates, and Qatar investing in advanced hospitals, genomic programs, and specialist treatment centers.

The European Union provides one of the world's most structured regulatory environments for advanced therapy medicinal products, creating opportunities for harmonized development while still requiring careful navigation of country-level reimbursement and hospital adoption. BRICS countries offer scale, patient diversity, and growing domestic innovation, particularly in China, India, Brazil, and South Africa, but they also present heterogeneous regulatory, pricing, and infrastructure conditions.

G7 markets remain central to premium innovation, intellectual property generation, clinical evidence development, and early commercial uptake. NATO is not a healthcare trade bloc, but many NATO members overlap with major biopharmaceutical markets, making the alliance relevant to supply chain resilience, biosecurity coordination, critical raw material access, and continuity planning for advanced therapy manufacturing networks.

Key Country Insights for Leading Cell Therapy Markets

The United States leads global cell therapy technology commercialization through FDA-regulated approvals, deep venture capital, large academic cancer centers, and strong CDMO capacity. Canada complements this with translational research, public healthcare evaluation, and advanced manufacturing initiatives. Mexico is strengthening clinical research and cross-border healthcare links, while Brazil is Latin America's most visible market for advanced therapy regulation, oncology demand, and domestic scientific capacity.

In Europe, the United Kingdom remains influential through the MHRA, NHS-linked evidence generation, and the Cell and Gene Therapy Catapult. Germany combines engineering strength, hospital adoption, and bioprocessing expertise, while France supports advanced therapies through national research institutions and public-private initiatives. Italy and Spain contribute major clinical centers and ATMP manufacturing experience, and Russia maintains scientific capabilities despite market access and geopolitical constraints.

Across Asia-Pacific, China is scaling cell therapy research, clinical trials, and domestic manufacturing under evolving NMPA oversight. India is building affordability-focused innovation and hospital-based capacity, supported by a large patient base and growing biotechnology sector. Japan has a distinctive regenerative medicine framework and strong iPSC science, Australia offers high-quality clinical trial infrastructure, and South Korea combines government support, biomanufacturing strength, and an active cell and gene therapy developer base.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize closed and automated manufacturing platforms that improve reproducibility, reduce operator dependency, and enable faster technology transfer across sites. Building scalable processes early is critical, especially for autologous therapies where scheduling, patient material variability, and chain-of-identity controls can determine commercial viability.

Companies should invest in robust potency assays, rapid microbiology, digital batch records, and data architectures that connect development, manufacturing, quality, and clinical outcomes. Partnerships with hospitals, logistics providers, CDMOs, and regulators can reduce execution risk. Leaders should also diversify suppliers for critical reagents, viral vectors, media, single-use consumables, and cryogenic logistics to improve resilience and reduce bottlenecks.

Research Methodology

This executive summary is developed using a structured secondary and market-intelligence methodology. Inputs include publicly available regulatory information from agencies such as the FDA, EMA, PMDA, NMPA, and national health authorities; clinical trial registries; peer-reviewed scientific literature; patent and regulatory filing reviews; product approval histories; and industry announcements from established cell therapy developers, technology vendors, and CDMOs.

Insights are triangulated across regulatory evidence, clinical development activity, manufacturing trends, regional healthcare infrastructure, and commercialization signals. The analysis emphasizes verified and observable market drivers rather than unsupported projections, with a focus on technology adoption, quality requirements, regional readiness, and strategic implications for stakeholders across the cell therapy technologies value chain.

Conclusion

Cell therapy technologies are becoming a core pillar of next-generation medicine as approved therapies, clinical pipelines, and manufacturing platforms continue to mature. The market's long-term potential depends on the industry's ability to convert complex biology into standardized, compliant, and scalable operations that can serve more patients across more indications.

The strongest opportunities will accrue to organizations that integrate automation, analytics, AI-enabled decision support, regulatory readiness, and resilient supply chains. As regional ecosystems expand and global competition intensifies, cell therapy technology leaders that combine scientific excellence with manufacturing discipline will be best positioned to shape the future of advanced therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Technologies Market, by Offering

• 7.1. Consumables
• 7.2. Equipment
  • 7.2.1. Bioreactors
  • 7.2.2. Cell Analyzers
• 7.3. Software & Services
  • 7.3.1. Data Management
  • 7.3.2. Quality Control

8. Cell Therapy Technologies Market, by Therapy Type

• 8.1. Allogeneic Cell Therapy
  • 8.1.1. Dendritic Cells
  • 8.1.2. Induced Pluripotent Stem Cells
  • 8.1.3. Natural Killer Cells
• 8.2. Autologous Cell Therapy
  • 8.2.1. Hematopoietic Stem Cells
  • 8.2.2. Mesenchymal Stem Cells
  • 8.2.3. T-Cells
• 8.3. Gene-Modified Cell Therapy
  • 8.3.1. CAR-T Cell Therapy
  • 8.3.2. TCR (T-Cell Receptor) Therapy

9. Cell Therapy Technologies Market, by Manufacturing Process

• 9.1. Cell Culture
  • 9.1.1. 2D Culture Systems
  • 9.1.2. 3D Culture Systems
• 9.2. Cell Expansion
  • 9.2.1. Adherent Culture
  • 9.2.2. Suspension Culture
• 9.3. Cell Separation
  • 9.3.1. Fluorescence-Activated Cell Sorting
  • 9.3.2. Magnetic-Activated Cell Sorting

10. Cell Therapy Technologies Market, by Delivery Method

• 10.1. Ex vivo
• 10.2. In vivo

11. Cell Therapy Technologies Market, by Application

• 11.1. Cardiovascular Disease
  • 11.1.1. Ischemic Heart Disease
  • 11.1.2. Peripheral Artery Disease
• 11.2. Musculoskeletal Disorders
  • 11.2.1. Osteoarthritis
  • 11.2.2. Rheumatoid Arthritis
• 11.3. Neurodegenerative Diseases
  • 11.3.1. Alzheimer's Disease
  • 11.3.2. Parkinson's Disease
• 11.4. Oncology
  • 11.4.1. Hematological Cancer
  • 11.4.2. Solid Tumors
    • 11.4.2.1. Breast Cancer
    • 11.4.2.2. Lung Cancer
    • 11.4.2.3. Prostate Cancer

12. Cell Therapy Technologies Market, by End User

• 12.1. Biopharmaceutical Companies
• 12.2. Hospitals
  • 12.2.1. Private Hospitals
  • 12.2.2. Public Hospitals
• 12.3. Research Institutes
  • 12.3.1. Government Research Centers
  • 12.3.2. University Academics

13. Cell Therapy Technologies Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Cell Therapy Technologies Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cell Therapy Technologies Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Adaptimmune Limited
• 17.2. Allogene Therapeutics Inc.
• 17.3. Atara Biotherapeutics, Inc.
• 17.4. Bellicum Pharmaceuticals, Inc.
• 17.5. Bluebird Bio Inc.
• 17.6. Cellectis SA
• 17.7. Century Therapeutics, Inc.
• 17.8. Charles River Laboratories International, Inc.
• 17.9. ElevateBio LLC
• 17.10. Gamida Cell Ltd.
• 17.11. GE HealthCare Technologies Inc.
• 17.12. Gilead Sciences, Inc.
• 17.13. Iovance Biotherapeutics, Inc.
• 17.14. Johnson & Johnson Services, Inc.
• 17.15. Legend Biotech USA Inc.
• 17.16. Novartis AG
• 17.17. Sartorius AG
• 17.18. STEMCELL Technologies Inc.
• 17.19. Takara Bio Inc.
• 17.20. Takeda Pharmaceutical Company Limited
• 17.21. Thermo Fisher Scientific Inc.
• 17.22. Vericel Corporation